Skip to content

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Big pharma earnings preview: what to expect from GSK and AstraZeneca Q1 results

Britain’s two largest drug makers both unveil their first quarter results on Wednesday, with investors eager to an update on how the Covid-19 crisis impacted the pairs performance.

Video poster image

GlaxoSmithKline (GSK) and AstraZeneca both unveil their first quarter (Q1) results on Wednesday, with investors keen to see the impact of the Covid-19 crisis on their financial performance.

AstraZeneca is looking to increase its total revenue by a ‘high single-digit to a low double-digit percentage’ and its core earnings per share (EPS) is forecast to increase by a ‘mid- to high-teens percentage’, according to its previous guidance.

GSK is expecting adjusted EPS to decline by -1% to -4% CER and is targeting a dividend pay-out of 80p per share in 2020.

Investors will be interested to see the impact of the coronavirus on both drug markers performance over their first three months of trading, though most companies guidance this year is heavily weighted towards the latter half of 2020.

GSK: technical analysis

Shares in GSK have been on a rip of late, with the market valuation gaining 28% since the March lows. The question from here is whether we can sustain this uptrend, as the stock pushes towards the prior peak of £18.25, according to Josh Mahony, senior market analyst at IG.

The short-term outlook will be dictated by the reaction to this confluence of resistance, with the ascending trendline and 76.4% Fibonacci resistance level meeting around £17.08. A break through this inflection point could bring about a bullish continuation signal.

However, given the existence of this current bearish rising wedge pattern, we could see some downside come into play if this zone of resistance is not broken. In particular, if we break below £16.43, things could start taking a more significant bearish turn.

Chart1
Chart1

AstraZeneca: technical analysis

AstraZeneca shares have experienced an incredible 41% upside since the March low, with the stock hitting a record high for three-weeks in a row.

This wider weekly chart highlights how significant this move has been, with a standard deviation channel indicating that things could be a little stretched at these levels.

For now we have not seen any bearish intraday signals, yet it could be prudent to be aware of a potential pullback if the short-term picture starts to sour somewhat.

Chart2
Chart2

How to trade stocks with IG

Looking to trade GSK and other stocks? Open a live or demo account with IG and buy (long) or sell (short) the asset using derivatives like CFDs and spread bets in a few easy steps:

  • Create an IG trading account or log in to your existing account

  • Enter ‘GlaxoSmithKline’ in the search bar and select it

  • Choose your position size

  • Click on ‘buy’ or ‘sell’ in the deal ticket

  • Confirm the trade

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Act on share opportunities today

Go long or short on thousands of international stocks with spread bets and CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take advantage while conditions prevail.

Live prices on most popular markets

  • Equities
  • Indices
  • Forex
  • Commodities


Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Sunday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.


For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.